1. CEMIP upregulates BiP to promote breast cancer cell survival in hypoxia
- Author
-
Anna Banach, Eric Roth, Jian Cao, Ya-Ping Jiang, Cem Kuscu, and Richard Z. Lin
- Subjects
0301 basic medicine ,autophagy ,genetic structures ,BiP ,Cell ,macromolecular substances ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,CEMIP ,medicine ,biology ,hypoxia ,Chemistry ,Autophagy ,Cell migration ,medicine.disease ,3. Good health ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Apoptosis ,030220 oncology & carcinogenesis ,Cancer cell ,biology.protein ,Cancer research ,Binding immunoglobulin protein ,Research Paper - Abstract
Cell migration-inducing protein (CEMIP) and binding immunoglobulin protein (BiP) are upregulated in human cancers, where they drive cancer progression and metastasis. It has been shown that CEMIP resides in the endoplasmic reticulum (ER) where it interacts with BiP to induce cell migration, but the relationship between the two proteins was previously unknown. Here we show that CEMIP mediates activation of the BiP promoter and upregulates BiP transcript and protein levels in breast cancer cell lines. Moreover, CEMIP overexpression confers protective adaptations to cancer cells under hypoxic conditions, by decreasing apoptosis, activating autophagy, and increasing glucose uptake, to facilitate tumor growth. We demonstrate that BiP signals downstream of CEMIP, modulating cellular resistance to hypoxia. Reducing BiP in CEMIP-expressing cells sensitized cells to hypoxia treatment, decreased glucose uptake, and resulted in tumor regression in vivo. Our study provides insights into the link between CEMIP and BiP expression and the pro-survival role they play in hypoxia. Better understanding of the mechanisms behind cancer cell adaptations to harsh tumor environments could lead to development of improved cancer treatments.
- Published
- 2019
- Full Text
- View/download PDF